Giuseppina Roscigno

List of Publications by Year
in descending order

24	1,168	471509 17	610901 24
papers	citations	h-index	g-index

24	24	24	2168
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 3989.	4.1	6
2	Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer. Molecular Therapy - Nucleic Acids, 2022, 28, 17-31.	5.1	25
3	miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer. Cancer Gene Therapy, 2021, 28, 413-426.	4.6	13
4	Identification of a novel RNA aptamer that selectively targets breast cancer exosomes. Molecular Therapy - Nucleic Acids, 2021, 23, 982-994.	5.1	29
5	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. Journal of the American College of Cardiology, 2021, 77, 2667-2676.	2.8	18
6	Modulating the Crosstalk between the Tumor and the Microenvironment Using SiRNA: A Flexible Strategy for Breast Cancer Treatment. Cancers, 2020, 12, 3744.	3.7	13
7	Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. Molecular Therapy - Nucleic Acids, 2020, 20, 176-185.	5.1	29
8	miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. International Journal of Molecular Sciences, 2020, 21, 2313.	4.1	13
9	Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. Cancers, 2019, 11, 1521.	3.7	29
10	The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. Molecular Therapy - Nucleic Acids, 2019, 18, 99-109.	5.1	33
11	The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. International Journal of Molecular Sciences, 2019, 20, 4687.	4.1	111
12	Highly Homogeneous Biotinylated Carbon Nanodots: Red-Emitting Nanoheaters as Theranostic Agents toward Precision Cancer Medicine. ACS Applied Materials & Interfaces, 2019, 11, 19854-19866.	8.0	61
13	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 13, 334-346.	5.1	43
14	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. International Journal of Cardiology, 2017, 244, 112-118.	1.7	10
15	Direct determination of small RNAs using a biotinylated polythiophene impedimetric genosensor. Biosensors and Bioelectronics, 2017, 87, 1012-1019.	10.1	51
16	MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget, 2017, 8, 19507-19521.	1.8	63
17	RYK promotes the stemness of glioblastoma cells via the WNT/Î²-catenin pathway. Oncotarget, 2017, 8, 13476-13487.	1.8	38
18	Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget, 2017, 8, 19592-19608.	1.8	267

#	Article	IF	Citations
19	MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget, 2016, 7, 580-592.	1.8	84
20	Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Molecular Therapy - Nucleic Acids, 2016, 5, e289.	5.1	60
21	miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS. Oncotarget, 2016, 7, 19531-19547.	1.8	36
22	Neutrophil Gelatinaseâ€“Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2015, 8, e002673.	3.9	38
23	miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells. PLoS ONE, 2013, 8, e74466.	2.5	84
24	A dominant mutation etiologic for human trichoâ€dentoâ€osseous syndrome impairs the ability of DLX3 to downregulate Î”Np63Î±. Journal of Cellular Physiology, 2011, 226, 2189-2197.	4.1	14